Targeted pill combo could spare some breast cancer patients from chemo
NCT ID NCT04158362
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a combination of the targeted drug abemaciclib plus hormone therapy works as well as standard chemotherapy for women with ER+ HER2- breast cancer that has spread to the liver, lungs, or other organs. About 180 participants will be randomly assigned to one of the two approaches. The main goal is to see how long the cancer stays under control, while also tracking quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abemaciclib (a targeted cancer pill) combined with hormone therapy (letrozole or anastrozole)
What this could lead to
If successful, this could show that a targeted pill plus hormone therapy works as well as or better than chemotherapy for people with advanced ER+ HER2- breast cancer that has spread to organs, potentially offering a less toxic first treatment option.
What could go wrong
This is a phase 3 trial, but it is still experimental. The combination may not improve progression-free survival compared to chemo, and side effects like diarrhea, fatigue, or blood clots are possible. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Eugène Marquis
Rennes, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France